A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

British Journal of Haematology

Volumn 153, Issue 1, 2011, Pages 66-75

  Lemery, Steven J ^a   Hsieh, Matthew M ^b   Smith, Aleah ^a   Rao, Sheila ^a   Khuu, Hanh M ^c   Theresa, Donohue ^a   Viano, Jennifer M ^a   Cook, Lisa ^a   Goodwin, Rose ^a   Boss, Carol ^a   Calandra, Gary ^d   Geller, Nancy ^a   Tisdale, John ^b   Childs, Richard ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d GENZYME CORPORATION   (United States)

Author keywords

BMT; CD34; Clinical research; Plerixafor; Stem cell mobilization homing

Indexed keywords

CD34 ANTIGEN; PLERIXAFOR;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOATING; CARDIOTOXICITY; CD34 SELECTION; COHORT ANALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPIPHORA; FATIGUE; FEMALE; FLATULENCE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; ORAL PARESTHESIA; PILOT STUDY; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINUS ARRHYTHMIA; SINUS BRADYCARDIA; SINUS TACHYCARDIA; STEM CELL MOBILIZATION; SUPRAVENTRICULAR PREMATURE BEAT; SYNCOPE; THROMBOCYTE; VIVID DREAM; VOLUNTEER; VOMITING;

ADOLESCENT; ADULT; ANTIGENS, CD34; COHORT STUDIES; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, CXCR4; YOUNG ADULT;

EID: 79952592158     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08547.x     Document Type: Article

References (22)

1. Aiuti, A., Webb, I.J., Bleul, C., Springer, T. & Gutierrez-Ramos, J.C. (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. The Journal of Experimental Medicine, 185, 111-120.
2. Brave, M., Farrell, A., Ching, L.S., Ocheltree, T., Pope, M.S., Lee, S.L., Saber, H., Fourie, J., Tornoe, C., Booth, B., Yuan, W., He, K., Justice, R. & Pazdur, R. (2010) FDA review summary: mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology, 78, 282-288.
3. Brissot, E., Chevallier, P., Guillaume, T., Delaunay, J., Ayari, S., Dubruille, V., Le Gouill, S., Mahe, B., Gastinne, T., Blin, N., Saulquin, B., Flandrois, G., Devys, A., Stocco, V., Cesbron, A., Dehaut, F., Moreau, P., Harousseau, J.L. & Mohty, M. (2009) Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors. Bone marrow transplantation, 44, 613-615.
4. Devine, S.M., Flomenberg, N., Vesole, D.H., Liesveld, J., Weisdorf, D., Badel, K., Calandra, G. & Dipersio, J.F. (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22, 1095-1102.
5. Devine, S.M., Vij, R., Rettig, M., Todt, L., McGlauchlen, K., Fisher, N., Devine, H., Link, D.C., Calandra, G., Bridger, G., Westervelt, P. & Dipersio, J.F. (2008) Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood, 112, 990-998.
6. Donahue, R.E., Jin, P., Bonifacino, A.C., Metzger, M.E., Ren, J., Wang, E. & Stroncek, D.F. (2009) Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood, 114, 2530-2541.
7. Flomenberg, N., Devine, S.M., Dipersio, J.F., Liesveld, J.L., McCarty, J.M., Rowley, S.D., Vesole, D.H., Badel, K. & Calandra, G. (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood, 106, 1867-1874.
8. Hubel, K., Liles, W.C., Broxmeyer, H.E., Rodger, E., Wood, B., Cooper, S., Hangoc, G., Macfarland, R., Bridger, G.J., Henson, G.W., Calandra, G. & Dale, D.C. (2004) Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Supportive Cancer Therapy, 1, 165-172.
9. Lack, N.A., Green, B., Dale, D.C., Calandra, G.B., Lee, H., MacFarland, R.T., Badel, K., Liles, W.C. & Bridger, G. (2005) A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clinical Pharmacology and Therapeutics, 77, 427-436.
10. Larochelle, A., Krouse, A., Metzger, M., Orlic, D., Donahue, R.E., Fricker, S., Bridger, G., Dunbar, C.E. & Hematti, P. (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood, 107, 3772-3778.
11. Liles, W.C., Broxmeyer, H.E., Rodger, E., Wood, B., Hubel, K., Cooper, S., Hangoc, G., Bridger, G.J., Henson, G.W., Calandra, G. & Dale, D.C. (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood, 102, 2728-2730.
12. Moncada, V., Bolan, C., Yau, Y.Y. & Leitman, S.F. (2003) Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion, 43, 495-501.
13. Pastore, D., Specchia, G., Mestice, A., Liso, A., Pannunzio, A., Carluccio, P., Buquicchio, C., Greco, G., Ciuffreda, L., Pietrantuono, G. & Liso, V. (2004) Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplantation, 33, 1083-1087.
14. Pulsipher, M.A., Chitphakdithai, P., Logan, B.R., Leitman, S.F., Anderlini, P., Klein, J.P., Horowitz, M.M., Miller, J.P., King, R.J. & Confer, D.L. (2009) Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood, 114, 2606-2616.
15. Rettig, M.P., Ramirez, P., Shannon, W.D., Uy, G.L., Lopez, S., Ritchey, J.K. & Dipersio, J.F. (2007) Kinetics of stem cell and lymphoid subset mobilization in response to intravenous (IV) AMD3100 in mouse and man. Blood (ASH Annual Meeting Abstracts) 110, Abstract 1203.
16. Singh, A.K., Savani, B.N., Albert, P.S. & Barrett, A.J. (2007) Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 13, 339-344.
17. Smith, A.L., Jungnam, J., Rao, S., Lundqvist, A., Cook, L.W., Goodwin, R.S., Catalina, R., Geller, N.L. & Childs, R.W. (2007) Significant alterations in T-Cell TH1 and TH2 cytokine gene profiles associated with G-CSF mobilization do not occur in T-cells mobilized with AMD3100. Blood (ASH Annual Meeting Abstracts), 110, Abstract 3277.
18. Stewart, D.A., Smith, C., Macfarland, R. & Calandra, G. (2009) Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 15, 39-46.
19. Sutherland, D.R., Anderson, L., Keeney, M., Nayar, R. & Chin-Yee, I. (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. Journal of hematotherapy, 5, 213-226.
20. Takahashi, Y., Tawab, A., Kurlander, R., Elshal, M., Bolan, C., Read, E.J., Leitman, S., McCoy, J.P., Lundqvist, A., Bahceci, E. & Childs, R. (2005) AMD3100 mobilized apheresis products are rich in T-cells that do not undergo a Th-2 type cytokine polarization: implications for allografting. Blood (ASH Annual Meeting Abstracts), 106 Abstract 296.
21. Vasu, S., Leitman, S.F., Tisdale, J.F., Hsieh, M.M., Childs, R.W., Barrett, A.J., Fowler, D.H., Bishop, M.R., Kang, E.M., Malech, H.L., Dunbar, C.E., Khuu, H.M., Wesley, R., Yau, Y.Y. & Bolan, C.D. (2008) Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood, 112, 2092-2100.
22. Visani, G., Lemoli, R.M., Tosi, P., Martinelli, G., Testoni, N., Ricci, P., Piccaluga, P.P., Pastano, R., Leopardi, G., Dizdari, A., Motta, M.R., Rizzi, S. & Tura, S. (1999) Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. British journal of haematology, 105, 775-779.